A role of human beta defensin-1 in predicting prostatic adenocarcinoma in cases of false-negative biopsy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Soon Auck | - |
dc.contributor.author | Kim, Ki Hong | - |
dc.contributor.author | Lee, Tae Jin | - |
dc.contributor.author | Park, Eon Sub | - |
dc.contributor.author | Kim, Mi Kyung | - |
dc.contributor.author | Myung, Soon Chul | - |
dc.date.accessioned | 2021-08-11T14:23:47Z | - |
dc.date.available | 2021-08-11T14:23:47Z | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 0903-4641 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7010 | - |
dc.description.abstract | The purpose of this study was to clarify the role of human beta defensin-1 (hBD-1) in predicting PAC in morphologically normal prostate glands. In total, 25 patients with a negative initial biopsy for PAC and diagnosed as PAC positive in subsequent biopsies performed within 1 year of the initial biopsy were included. As a control group, 22 patients negative for PAC in at least three consecutive histologic examinations were selected. Expression of hBD-1 was analyzed separately via immunohistochemistry in paired cores of non-neoplastic gland and PAC in the false-negative group and control group. Loss of hBD-1 expression was observed in 95.6% and 90.0% PAC cases with Gleason Patterns 3 and 4 in repeat biopsies, respectively. hBD-1 loss of basal cells in 40 (85.1%) previous non-neoplastic biopsy cores in the false-negative group was observed, in contrast to preserved basal cell expression of hBD-1 in 64 (72.7%) biopsy cores in the control group (p = 0.001). Multivariate logistic regression analysis showed that hBD-1 basal cell loss (20% of prostatic glands in total cores) is an independent factor for predicting PAC (odds ratio: 4.739, confidence interval: 1.093-20.554, p = 0.038). hBD-1 loss of basal cells is a useful indicator to identify extremely high-risk patients with initially negative biopsy. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Blackwell Publishing Inc. | - |
dc.title | A role of human beta defensin-1 in predicting prostatic adenocarcinoma in cases of false-negative biopsy | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/apm.12749 | - |
dc.identifier.scopusid | 2-s2.0-85028978003 | - |
dc.identifier.wosid | 000416437400004 | - |
dc.identifier.bibliographicCitation | APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, v.125, no.12, pp 1063 - 1069 | - |
dc.citation.title | APMIS : acta pathologica, microbiologica, et immunologica Scandinavica | - |
dc.citation.volume | 125 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1063 | - |
dc.citation.endPage | 1069 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalResearchArea | Pathology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Pathology | - |
dc.subject.keywordAuthor | Human beta defensin-1 | - |
dc.subject.keywordAuthor | prostate adenocarcinoma | - |
dc.subject.keywordAuthor | immunohistochemistry | - |
dc.subject.keywordAuthor | false negative | - |
dc.subject.keywordAuthor | repeat biopsy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.